A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type i (IGF-1R) demonstrating unique molecular properties

导出原文传递

翻译打印收藏纠错

作者： Schanzer,J.M. ^[1] ; Wartha,K. ^[2] ; Croasdale,R. ^[3] ; Moser,S. ^[4] ; Künkele,K.-P. ; Ries,C. ; Scheuer,W. ; Duerr,H. ; Pompiati,S. ; Pollman,J. ; Stracke,J. ; Lau,W. ; Ries,S. ; Brinkmann,U. ; Klein,C. ; Umana,P.

作者单位： Large Molecule Research, Pharmaceutical Research and Early Development, Roche Diagnostics GmbH ^[1] Discovery Oncology, Pharmaceutical Research and Early Development, Roche Diagnostics GmbH ^[2] Roche Glycart AG, CH-8952 Schlieren, Switzerland ^[3] Boehringer Ingelheim, A-1121 Vienna, Austria ^[4]

发布时间 2014-12-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The Journal of biological chemistry

2014年289卷27期

18693-18706页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type i (IGF-1R) demonstrating unique molecular properties

The Journal of biological chemistry

相似文献

The Journal of biological chemistry

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type i (IGF-1R) demonstrating unique molecular properties

The Journal of biological chemistry

相似文献

The Journal of biological chemistry

相关期刊

检索历史清除